Retrieve Medical (RMHI) 10-K 13 Jan 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2015	Jan. 12, 2016	Mar. 31, 2015
Document and Entity Information:
Entity Registrant Name	PEAK PHARMACEUTICALS, INC.
Document Type	10-K
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Entity Central Index Key	1,452,804
Current Fiscal Year End Date	--09-30
Entity Common Stock, Shares Outstanding		78,363,562
Entity Public Float			$ 9,906,505
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Current Assets
Cash	$ 201,656	$ 451,431
Prepaid Expenses	7,250	6,838
Assets of Discontinued Operations Held for Sale	50,383
Total Current Assets	259,289	458,269
Fixed Assets, Net of Amortization	1,336
Intangible Asset, Net of Amortization	18,245	30,139
Deposit	2,500	2,500
Total Assets	281,370	490,908
Current Liabilities
Accounts Payable	43,238	43,534
Account Payable - Related Parties	27,000	10,893
Accrued Liabilities	39,151
Liabilities of Discontinued Operations Held for Sale	179,243
Total Current Liabilities	288,632	54,427
Total Liabilities	$ 288,632	$ 54,427
Commitments and Contingencies
Stockholders' Equity
Common stock	$ 7,836	$ 7,816
Additional Paid-in Capital	6,151,997	4,287,720
Accumulated Deficit	(6,167,095)	(3,859,055)
Total Stockholders' Equity (Deficit)	(7,262)	436,481
Total Liabilities and Stockholders' Equity (Deficit)	$ 281,370	$ 490,908
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	325,000,000	325,000,000
Common stock, shares issued	78,363,562	78,163,562
Common stock, shares outstanding	78,363,562	78,163,562

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Expenses
General and Administrative	$ 2,326,985	$ 2,669,863
Cost Associated with Exploring Business Opportunity		412,114
Amortization	11,893	4,861
Total Operating Expenses	2,338,878	3,086,837
Loss From Operations	(2,338,878)	(3,086,837)
Other Income and (Expense)
Interest Expense	(2,202)	(696,628)
Gain on Extinguishment of Debt		24,650
Total Other Income and (Expense)	(2,202)	(671,978)
Net From Continuing Operations	(2,341,080)	(3,758,815)
Income From Operations of Discontinued Canna-Pet Component	33,040
Net Loss	$ (2,308,040)	$ (3,758,815)
Basic and Diluted (Loss) per Common Share	$ (0.03)	$ (0.05)
Weighted Average Number of Common Shares Outstanding	78,320,084	75,229,245

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid in Capital	Deficit Accumulated	Total Stockholders' Equity (Deficit)
Stockholder Equity at Sep. 30, 2013		$ 33,075	$ 27,925	$ (100,240)	$ (39,240)
Shares Issued at Sep. 30, 2013		330,750,000
Shares Issued for Cash		$ 3,782	1,036,218		1,040,000
Shares Issued for Cash (Shares)		37,825,000
Shares Cancelled	$ 30,000	$ (30,000)	30,000
Shares Cancelled (Shares)		(300,000,000)
Shares Repurchased and Cancelled	30,000	$ (3,325)	(121,675)		(125,000)
Shares Repurchased (Shares)		(33,250,000)
Shares Issued for Services to Employees and Directors		$ 3,758	246,801		250,559
Shares Issued for Services to Employees and Directors (Shares)		37,583,998
Shares Issued for Services to Non-Employees	$ 787,759	$ 53	537,147		537,200
Shares Issued for Services to Non-Employees (Shares)		526,666
Shares Issued for Debt Conversion		$ 473	659,167		659,640
Shares Issued for Debt Conversion (shares)	3,248,898	4,727,898
Equity Based Compensation	$ 1,222,357		1,222,357		1,222,357
Effect of Beneficial Conversion Feature	649,780		649,780		649,780
Net Loss	(3,758,815)			(3,758,815)	(3,758,815)
Stockholder Equity at Sep. 30, 2014	436,481	$ 7,816	4,287,720	(3,859,055)	436,481
Shares Issued at Sep. 30, 2014		78,163,562
Shares Issued for Services to Non-Employees	36,000	$ 20	35,980		36,000
Shares Issued for Services to Non-Employees (Shares)		200,000
Equity Based Compensation	1,828,297		1,828,297		1,828,297
Net Loss	(2,308,040)			(2,308,040)	(2,308,040)
Stockholder Equity at Sep. 30, 2015	$ (7,262)	$ 7,836	$ 6,151,997	$ (6,167,095)	$ (7,262)
Shares Issued at Sep. 30, 2015		78,363,562

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows From Operating Activities:
Net Loss	$ (2,308,040)	$ (3,758,815)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Depreciation	850
Amortization of Website	11,893	4,861
Effect of Beneficial Conversion Feature		649,780
Shares Issued for Services to Non-Employees	36,000	787,759
Equity Based Compensation	1,828,297	1,222,357
Gain on Conversion of Debt		(24,650)
Debt Issued for Interest		102,932
Changes in Operating Assets and Liabilities
Increase/Decrease in Prepaid Expenses	(411)	(6,838)
Increase/Decrease in Assets of Discontinued Operations Held for Sale	(50,383)
Increase/Decrease in Deposits		(2,500)
Increase/Decrease in Accounts Payable and Accrued Liabilities	38,855	80,746
Increase/Decrease in Accounts Payable - Related Parties	16,107	10,893
Increase/Decrease in Liabilities of Discontinued Operations Held For Sale	179,243
Net Cash Used in Operating Activities	(247,589)	(933,475)
Cash Flows From Investing Activities:
Purchase of Equipment	(2,186)
Website Development Cost		(35,000)
Net Cash Used in Investing Activities	(2,186)	(35,000)
Cash Flows From Financing Activities:
Sale of Stock		1,040,000
Shares Redeemed for Cash		(125,000)
Proceeds from Note Payable		500,000
Net Cash Provided by Financing Activities		1,415,000
Increase (Decrease) in Cash	(249,775)	446,525
Initial Cash	451,431	4,906
Final Cash	(201,656)	451,431
Supplemental Disclosures
Cash Paid for Interest	$ 2,250
Non-cash Financing Activities:
Common Shares for Settlement of Debt		9,860
Conversion of debt into common shares		649,780
Shares Cancelled		$ 30,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2015
Notes
Summary of Significant Accounting Policies	Note 1 – Summary of Significant Accounting Policies Throughout this report, the terms “our,” “we,” “us,” and the “Company” refer to Peak Pharmaceuticals, Inc. and its subsidiary. Peak Pharmaceuticals, Inc. was incorporated in Nevada on December 18, 2007 as Surf A Movie Solutions Inc., which was previously engaged in the development, sales and marketing of online video stores. We decided to change our business objective and in connection therewith we first changed our name to Frac Water Systems, Inc. and explored the possibilities of providing economically and environmentally sound solutions for the treatment and recycling of wastewater resulting principally from oil and gas exploration and production activities. On December 31, 2013, we determined not to move forward with that business model. On March 14, 2014, we changed our name to Cannabis Technology Corp. The name change was made in connection with our entry into the business of manufacturing and marketing pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of cannabis, for the treatment of various conditions and diseases. On December 23, 2014, we changed our name again to Peak Pharmaceuticals, Inc. This name change was made to make our name more consistent with our business operations and plans relating to development, manufacturing and marketing of hemp-based nutraceutical and supplement products for the human and animal health markets. During September, 2015 we decided to discontinue the marketing of animal supplements. See Note 2 Discontinued operations. We are currently evaluating other business opportunities in the hemp space. Financial statements prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate a company’s continuation as a going concern. We have incurred net losses since inception. In addition, we have an accumulated deficit of $6,167,095 as of September 30, 2015. This condition raises substantial doubt as to our ability to continue as a going concern. In response to these conditions, we are evaluating raising additional capital through the sale of equity securities, through an offering of debt securities or through borrowings from financial institutions or individuals. These financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. Basis of Consolidation The consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. (“BioPharma”). All inter-company balances and transactions among the companies have been eliminated upon consolidation. Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues and expenses during the years reported. Actual results may differ from these estimates. Financial Instruments Our financial instruments consist of cash, and payables. The carrying values of these instruments approximate fair value because of the short term maturities of these instruments. Inventory Inventory, which is included in assets of discontinued operations held for sale, consists of finished goods and is carried at the lower of cost or market on a first in first out basis. Fair Value Measurements: Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC)” Topic 820, Fair Value Measurements and Disclosures ("ASC 820"), provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange. Level 2 – Pricing inputs are other than quoted prices in active markets, but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts, or priced with models using highly observable inputs. Level 3 – Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights. Intangible asset Intangible asset is our website and is being amortized over the expected useful life which we estimate to be three years. Amortization expense charged to operations for the years ended September 30, 2015 and 2014, were $11,893 and $4,861 , respectively. Long-lived assets On a periodic basis, management assesses whether there are any indicators that the value of our long-lived assets may be impaired. An asset’s value may be impaired only if management’s estimate of the aggregate future cash flows, on an undiscounted basis, to be generated by the asset are less than the carrying value of the asset. Our only longed lived asset is our website. If impairment has occurred, the loss is measured as the excess of the carrying amount of the asset over its fair value. Our estimates of aggregate future cash flows expected to be generated by our long-lived asset are based on a number of assumptions that are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in their impairment analyses may not be achieved. As of September 30, 2015, there was no asset impairment. Revenue Recognition We recognize revenue from products sold when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable and collection is reasonably assured. Revenue represents the sale of products and related shipping fees. Revenue is included in income from operations of BioPharma’s discontinued Canna-Pet component. Cost of Revenue Cost of revenue includes the cost of products sold and shipping costs attributable to the revenue. Cost of revenue is included in income from operations of BioPharma’s discontinued Canna-Pet component. Shipping Costs Shipping costs of $116,287 are included in general and administrative expenses of BioPharma’s discontinued Canna-Pet component. Expenses associated with exploring business opportunities Through the period ended December 31, 2014, we were exploring opportunities related to solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and productions activities. We determined not to proceed in that industry. Costs included legal fees, fees associated with the assumption of certain notes and other payments under the Agreement, consulting fees, attending conferences, web development, and travel. These costs include a non-cash charge of $102,932 which is the accrued interest on debt assumed and $2,413 which is the fair value of options granted in connection with that business. Research and Development Expenditures for research activities relating to product development and improvement are charged to expense as incurred. We incurred $13,051 and $30,000 in research and development expenses for the years ended September 30, 2015 and 2014, respectively. Equity Based Payments Equity based payments are accounted for in accordance with ASC Topic 718, Compensation – Stock Compensation. The compensation cost is based upon fair value of the equity instrument at the date grant. The fair value has been estimated using the Black-Sholes option pricing model. In addition, payments made to non-employees are accounted for in accordance with ASC Topic 505, Equity-Based payments to Non-Employees. Income Taxes The provision for income taxes is determined in accordance with the provisions of ASC Topic 740, Accounting for Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements, uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. For the years ended September 30, 2015 and 2014 we did not have any interest and penalties or any significant unrecognized uncertain tax positions. Loss per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for the period, and diluted earnings per share is computed by including Common Stock equivalents outstanding for the period in the denominator. We have not issued any potentially dilutive common shares. At September 30, 2015 and 2014 any equivalents would have been anti-dilutive as we had losses for the periods then ended. Recent Pronouncements From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. ASU Update 2014-15 Presentation of Financial Statements-Going Concern (Sub Topic 205-40) issued August 27, 2014 by FASB defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern. The additional disclosure requirement is effective after December 15, 2016 and will be evaluated as to impact and implemented accordingly. In addition, the FASB issued Accounting Standards Update No. 2014-09 (Revenue from Contracts with Customers), which is effective for annual reporting periods beginning after December 15, 2016. We have not yet assessed the impact, if any, of adopting this standard.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Sep. 30, 2015
Notes
Discontinued Operations	Note 2 - Discontinued Operations During September 2015, we determined to discontinue operations of our subsidiary, Peak BioPharma Corp. (“BioPharma”) which was in the business of marketing animal feed supplements containing phytocannabinoids and put the assets and business up for sale. We decided to sell this business primarily due to recent regulatory events. The business was disposed of as of October 1, 2015. The assets and liabilities of the discontinued operations are presented separately under the captions “Assets of discontinued operations held for sale” and “Liabilities of discontinued operations held for sale,” respectively, in the accompanying Consolidated Balance Sheets at September 30, 2015, and consist of the following: Assets of discontinued operations held for sale: Inventory $ 41,705 Deposits 8,678 Total assets $ 50,383 Liabilities of discontinued operations held for sale: Accounts payable $ 124,396 Royalty payable 39,506 Other liabilities 15,341 $ 179,243 The income from discontinued operations presented in the statements of operations consist of the following for the year ended September 30, 2015: Revenues $ 1,039,393 Cost of goods sold (305,295) General and administrative expenses (700,160) Depreciation (850) Interest (48) $ 33,040 There were no assets or liabilities, nor any operations, which related to discontinued operations in the year ended September 30, 2014.

Intangibles

Intangibles	12 Months Ended
	Sep. 30, 2015
Notes
Intangibles	Note 3 - Intangibles Intangibles at September 30, 2015 and 2014, consists of a Website, $35,000, less accumulated amortization of $11,893 and $4,861, respectively. The website is being amortized over three years. Estimated future amortization expense related to intangible property as of September 30, 2015 is as follows: Years ending September 30, Total Amortization 2016 $ 11,667 2017 6,578 $ 18,245

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2015
Notes
Related Party Transactions	Note 4 –Related Party Transactions Parties, which can be corporations or individuals, are considered to be related if we have the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Companies are also considered to be related if they are subject to common control or common significant influence. Accounts payable – related parties are the amounts payable to officers and directors of the Company for reimbursement of expenses they incurred on behalf of the Company as well as Director fees.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Sep. 30, 2015
Notes
Commitments and Contingencies	Note 5 – Commitments and Contingencies Canna-Pet License Agreement In July, 2014, through our wholly-owned subsidiary, Peak BioPharma Corp., we entered into a License Agreement (the “License Agreement”) with a Washington limited liability corporation (“Licensor”), which owns the brand name “Canna-Pet” and certain related intellectual property including, but not limited to, trademarks and copyrights, formulations, recipes, production processes and systems, websites, domain names, customer lists, supplier lists, trade secrets and know-how, and other related intellectual property (collectively, the “Licensed Intellectual Property”), used by Licensor in the conduct of its business related to the production and sale of medical products made from industrial hemp which are intended exclusively for consumption by pets. Pursuant to the License Agreement, Licensor granted to us a perpetual, exclusive, world-wide license to use the Licensed Intellectual Property in conjunction with our business and the production and sale of medical products made from industrial hemp as well as the right to sublicense the Licensed Intellectual Property to third parties. The License Agreement gives us the right to produce and sell existing products utilizing the Licensed Intellectual Property and to develop new products, jointly with Licensor or otherwise, based upon the Licensed Intellectual Property. The License Agreement provides us with an immediate revenue source and access to Licensor’s customer base. During the term of the license, all intellectual property rights in and to the Licensed Intellectual Property remain the exclusive property of Licensor. In consideration of the grant of the license, we have agreed to pay Licensor license fees in the form of royalty payments calculated on the basis of gross proceeds received by us from sales of products manufactured, marketed or sold by us utilizing the Licensed Intellectual Property or any subsequently developed intellectual property which is jointly owned by us and Licensor. The royalty will be calculated and paid by us on a quarterly basis using calendar quarters ending March 31, June 30, September 30, and December 31 each year and will be equal to fifteen percent (15%) of the first $1,000,000 of gross proceeds received by us during the quarter and ten percent (10%) on gross proceeds in excess of $1,000,000 received by us during the quarter. On or before the date, which is 45 days following the end of each calendar quarter, we will calculate the amount of the royalty due to Licensor for that quarter and will make payment in full of such amount to Licensor. For purposes of calculating the amount of royalty due for each quarter, “gross proceeds” will not include amounts received by us as payments for any and all taxes, duties, governmental charges, sales expenses, freight or shipping charges, and the like. Commencing in 2015, we have agreed to pay Licensor a guaranteed minimum royalty amounts based upon the gross proceeds received by us from the sale of products (the “License Based Products”) utilizing the Licensed Intellectual Property or subsequently developed jointly owned intellectual property. The guaranteed minimum royalty payments are as follows: Time Period Minimum Annual License Fee January 1, 2015 through December 31, 2015 Calculated based on gross proceeds equal to twice the verifiable sales of License Based Products for the calendar year ended December 31, 2014, with royalties equal to 15% on gross proceeds of up to $4,000,000 for the year and 10% on gross proceeds in excess of $4,000,000. January 1, 2016 through December 31, 2016 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2017 through December 31, 2017 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2018 through December 31, 2018 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2019 through December 31, 2019 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2020 through December 31, 2020, and all succeeding years The minimum annual royalty payment for the calendar year beginning January 1, 2020 and for all subsequent calendar years will be equal to the minimum annual royalty payment calculated for the calendar year ended December 31, 2019. All royalty payments made by us during any calendar year will be credited against the minimum annual royalty amounts due and payable by us for such year. In the event that the aggregate amount of royalties’ payable by us for any calendar year are not sufficient to satisfy our minimum annual royalty payment obligation for that year, we will be obligated to pay the unpaid balance of the minimum royalty amount to Licensor on or before February 28 of the following year Royalty expense for the year ended September 30, 2015 was $139,655 and is included in income from operations of BioPharma’s discontinued Canna-Pet component and liabilities of discontinued operations held for sale. There were no royalty expenses in the year ended September 30, 2014. Subsequent to September 30, 2015 all of our obligations under the agreement were terminated. (See Note 10 – Subsequent Events). Operating Lease We lease office and lab space under an operating lease, which expires August 31, 2016. The lease may be cancelled upon a 30-day notice. There are no automatic extension periods in the lease. Subsequent to September 30, 2015 we exercised our rights and notified the landlord that we would vacate the space in November 2015. Rent expense was $23,791 and $4,667 for the years ended September 30, 2015 and 2014, respectively.

Stockholders' Equity and Option

Stockholders' Equity and Options	12 Months Ended
	Sep. 30, 2015
Notes
Stockholders' Equity and Options	Note 6 – Stockholders’ Equity On March 11, 2014 our board of directors authorized a 1.5 for 1 forward split of our common stock in the form of a stock dividend (the “Stock Split”). In connection therewith, Company shareholders of record as of the close of business on March 27, 2014, the record date, received an additional .5 shares of our common stock for each share of our common stock held by them on the record date. Accordingly, all references to numbers of common shares and per-share data in the accompanying financial statements have been adjusted to reflect the Stock Split on a retroactive basis. On October 10, 2013, we issued 30,000,000 shares at $0.0067 per share, to a then officer of the Company, for total proceeds of $200,000. The shares were valued based upon the prior price paid in a prior transaction as there was no public trading at that time. On March 11, 2014 we repurchased 29,500,000 of these shares for an aggregate of $100,000. Prior to the repurchase, the officer and director resigned. In addition, on October 10, 2013, a former officer and director and a former director of ours delivered to us an aggregate of 300,000,000 shares of common stock of ours for cancellation. The cancellation of these shares was made in conjunction with the resignation of the positions they held. On October 15, 2013, we issued 3,750,000 shares at $0.0067 per share, to two directors of the Company for total proceeds of $25,000. The shares were valued based upon prior price paid in a prior transaction as there was no public trading at that time. On January 30, 2014 in connection with the termination of the JV Agreement and the resignation of the two directors, we repurchased these 3,750,000 shares for $25,000, the amount paid. On November 15, 2013, we issued 1,479,000 shares of our common stock in settlement for $34,510 due to a former related party. The shares were valued at $0.015 per share, the trading value on that date. On March 11, 2014, we issued 37,584,000 shares to 3 individuals and their assignees for services rendered. The shares were valued at $0.0067 per share, the amount paid by the Company to repurchase shares on the same date. The total amount, $250,599 was recognized as equity based compensation. During the period from April through September, we sold a total of 4,075,000 shares of our common stock at a price of $0.20 per share for total proceeds of $815,000. The price per share was negotiated with the investors. There was no cost attributed to these sales. On May 15, 2014 we entered into an agreement for investor relation services. The agreement provided for the issuance of 466,666 shares of our common stock. Pursuant to the agreement the stock was earned in June and July 2014. The stock was valued at $476,000, $1.02 per share, the trading value at the date earned and was charged to expense. On June 25, 2014 we entered into an agreement for public and investor relations services. The agreement is for a period of 90 days. The agreement requires the fee to be settled by our issuance of 60,000 restricted shares of our common stock. The shares were issued on July 14, 2014 and are valued at $61,200, $1.02 per share, the trading value, and has been charged to expense. On June 30, 2014 we issued 3,248,898 shares of our common stock in connection with the conversion of $649,780 in debt as per the debt agreement. On December 22, 2014, pursuant to a Placement Agent Agreement, we issued 200,000 restricted shares of our common stock. The shares were valued at $36,000, $0.18 per share, the trading value, and charged to stock based compensation. Note 7 – Options In 2013 we issued options to purchase 375,000 shares of our common stock. The options have a term of 10 years, are exercisable at $0.0067 per share and vested twelve months from the date of issuance, October 10, 2013. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $2,413. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 130% Risk Free interest rate 2.71 Dividend yield (on common stock) - During October 2013 through December 31, 2013 we issued options to purchase 1,125,000 shares of our common stock (375,000 to each of our Chief Executive Officer and two Directors). The options had a term of 10 years, were exercisable at $0.0067 per share and vested one year from the date of issuance. In addition, we issued options to purchase 262,500 shares of our common stock to our Chief Financial Officer. The options had a term of 10 years, were exercisable at $0.0067 per share and vested quarterly over the next year. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $5,859. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model Expected life (in years) 10 Volatility (based on a comparable companies) 130% Risk Free interest rate 2.71% Dividend yield (on common stock) - In January 2014 all of the option issued to the officers and directors were cancelled. In March 2014, we issued non-qualified options to purchase 2,916,000 shares of our common stock for services rendered to a director of the Company. The options have a term of 10 years, are exercisable at $0.0067 per share and vested when they were issued. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $9,078. The options have been expensed as equity based compensation. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 123% Risk Free interest rate 2.73% Dividend yield (on common stock) - In May 2014, we issued non-qualified options to purchase 4,500,000 shares of our common stock to certain officers of the Company. The options are exercisable at $0.20 per share and have graded vesting over 4 years. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $4,415,649. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 123% Risk Free interest rate 2.56% Dividend yield (on common stock) - As per guidance in the ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), we are amortizing the fair value of the options on a straight line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards (graded vesting attribution method). The estimated future expense related to existing stock options is a follows: Years ending September 30, 2016 $ 882,766 2017 407,886 2018 86,961 $ 1,377,613 The following is a summary of outstanding stock options issued to employees and directors as of September 30, 2015: Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding October 1, 2013 - $ - - $ - Issued 8,803,500 $ 0.0067- 0.20 - - Cancelled 1,387,500 $ 0.0067 - - Outstanding September 30, 2014 7,416,000 $ 0.0067 - 0.20 $ - Issued - - - Cancelled - - - Outstanding September 30, 2015 7,416,000 $0.0067 - $0.20 8.57 - Exercisable 4,391,000 $ $0.0067 - $0.20 8.52 $ - The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of September 30, 2015: Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding October 1, 2013 - $ - - $ - Issued 375,000 $0.0067 - Cancelled - - Outstanding September 30, 2014 375,000 $0.0067 - $ - Issued - - Cancelled - - Outstanding September 30, 2015 375,000 $0.0067 8.05 $ - Exercisable 375,000 $0.0067 8.05 $ - Total option expense for the years ended September 30, 2015 and 2014 was $1,828,297 and $1,222,357, respectively.

Interest

Interest	12 Months Ended
	Sep. 30, 2015
Notes
Interest	Note 8 – Interest On October 10, 2013, we entered into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Produced Water Solutions (“PWS”) and Montrose Capital Limited (“Montrose”) related to the termination of a June 13, 2013 Term Sheet (the “Term Sheet”) among us, PWS and Montrose. The Term Sheet contemplated a $250,000 bridge financing for PWS involving the sale of $250,000 in principal amount of secured convertible promissory notes of PWS (the “PWS Notes”) and a subsequent reverse triangular merger (the “Merger”) among us, PWS and the shareholders of PWS in which PWS would become a wholly-owned subsidiary of ours. On July 1, 2013 the $250,000, bridge financing was completed and the PWS Notes were issued. The Notes were subject to mandatory conversion at the effective time of the Merger into securities of ours. The parties to the Settlement Agreement subsequently determined not to proceed with the Merger, choosing instead to have us engage directly in the Business pursuant to a Joint Venture Agreement. As a result, we became liable for $602,932 in short term notes, which include the original principal of $500,000 and accrued interest of $102,932. On June 30, 2014 the Holders agreed to convert the Notes into common stock of the Company at a conversion price of $0.20 per share for the outstanding principal of $602,932 and accrued interest of $46,848. We issued 3,248,898 share of our common stock to the Holders. In accordance with guidance in ASC Topic 470, Debt, we recognized a beneficial conversion feature to the debt and wrote-off the discount at the date of conversion. The discount of $649,780 was recorded as interest expense.

Income Tax

Income Tax	12 Months Ended
	Sep. 30, 2015
Notes
Income Tax	Note 9 – Income Tax Income tax provision (benefit) for the years ended September 30, 2015 and 2014 is summarized below: 2015 2014 Current: Federal $ - $ - State - - Total current - - Deferred: Federal (155,900 ) (350,400 ) State (14,200 ) (31,500 ) Total deferred (170,100 ) (381,900 ) Increase in valuation allowance 170,100 381,900 Total provision $ - $ - The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate before provision for income taxes. The sources and tax effect of the differences are as follows: 2015 2014 Income tax provision at the federal statutory rate 34.0 % 34.0 % State income taxes, net of federal benefit 3.1 % 3.1 % Effect of net operating loss (37.1 %) (37.1 %) - % - % Components of the net deferred income tax assets at September 30, 2015 and 2014 were as follows: 2015 2014 Net operating loss carryover $ 840,500 $ 381,900 In March 2014 there was a significant change in control of the Company which resulted in a loss of NOL carryforwards available through that date. ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of evidence, it is more than likely than not that some portion or all of the deferred tax assets will not be recognized. After consideration of all the evidence, both positive and negative, management has determined that a $552,000 and $381,900 llowance at September 30, 2015 and 2014, respectively, is necessary to reduce the deferred tax assets to the amount that will more likely than not be realized. The change in the valuation allowance for the current year is $170,100. As of September 30, 2015, we have a net operating loss carry forward of approximately $840,464. The loss will be available to offset future taxable income. If not used, this carry forward will expire as follows in 2035. There are open statutes of limitations for taxing authorities in federal and state jurisdictions to audit our tax returns from 2011 through the current period. Our policy is to account for income tax related interest and penalties in income tax expense in the statement of operations. There have been no income tax related interest or penalties assessed or recorded. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This pronouncement also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. For the years ended September 30, 2015 and 2014 we did not have any interest and penalties associated with tax positions. As of September 30, 2015 we did not have any significant unrecognized uncertain tax positions.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2015
Notes
Subsequent Events	Note 10 – Subsequent Events On October 12, 2015, we entered into an agreement for the termination (“Termination Agreement”) of the Canna-Pet License Agreement, effectively selling the discontinued operations. The Termination Agreement contained the following provisions: · Termination of License · Return of Licensed Intellectual Property · Return of Other Property · Office Space, Equipment and Employees · Consideration. · Collections The execution of the Termination Agreement resulted in in a gain on sale of the discontinued operations of approximately $92,671, which will be reflected in subsequent financial statements. Management has evaluated all activity and concluded that no other subsequent events have occurred that would require recognition in these financial statements or disclosure in the notes to these financial statement.

Summary of Significant Accoun15

Summary of Significant Accounting Policies: Basis of Consolidation (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the financial statements of the Company and our wholly owned subsidiary Peak BioPharma Corp. (“BioPharma”). All inter-company balances and transactions among the companies have been eliminated upon consolidation.

Summary of Significant Accoun16

Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and revenues and expenses during the years reported. Actual results may differ from these estimates.

Summary of Significant Accoun17

Summary of Significant Accounting Policies: Financial Instruments (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Financial Instruments	Financial Instruments Our financial instruments consist of cash, and payables. The carrying values of these instruments approximate fair value because of the short term maturities of these instruments.

Summary of Significant Accoun18

Summary of Significant Accounting Policies: Inventory (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Inventory	Inventory Inventory, which is included in assets of discontinued operations held for sale, consists of finished goods and is carried at the lower of cost or market on a first in first out basis.

Summary of Significant Accoun19

Summary of Significant Accounting Policies: Fair Value Measurements (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Fair Value Measurements:	Fair Value Measurements: Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC)” Topic 820, Fair Value Measurements and Disclosures ("ASC 820"), provides a comprehensive framework for measuring fair value and expands disclosures which are required about fair value measurements. Specifically, ASC 820 sets forth a definition of fair value and establishes a hierarchy prioritizing the inputs to valuation techniques, giving the highest priority to quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable value inputs. ASC 820 defines the hierarchy as follows: Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange. Level 2 – Pricing inputs are other than quoted prices in active markets, but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts, or priced with models using highly observable inputs. Level 3 – Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights.

Summary of Significant Accoun20

Summary of Significant Accounting Policies: Intangible and Long Lived Assets (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Intangible and Long Lived Assets	Intangible asset Intangible asset is our website and is being amortized over the expected useful life which we estimate to be three years. Amortization expense charged to operations for the years ended September 30, 2015 and 2014, were $11,893 and $4,861 , respectively. Long-lived assets On a periodic basis, management assesses whether there are any indicators that the value of our long-lived assets may be impaired. An asset’s value may be impaired only if management’s estimate of the aggregate future cash flows, on an undiscounted basis, to be generated by the asset are less than the carrying value of the asset. Our only longed lived asset is our website. If impairment has occurred, the loss is measured as the excess of the carrying amount of the asset over its fair value. Our estimates of aggregate future cash flows expected to be generated by our long-lived asset are based on a number of assumptions that are subject to economic and market uncertainties. As these factors are difficult to predict and are subject to future events that may alter management’s assumptions, the future cash flows estimated by management in their impairment analyses may not be achieved. As of September 30, 2015, there was no asset impairment.

Summary of Significant Accoun21

Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Revenue Recognition	Revenue Recognition We recognize revenue from products sold when there is persuasive evidence of an arrangement, delivery has occurred or services have been rendered, the sales price is determinable and collection is reasonably assured. Revenue represents the sale of products and related shipping fees. Revenue is included in income from operations of BioPharma’s discontinued Canna-Pet component.

Summary of Significant Accoun22

Summary of Significant Accounting Policies: Cost of Revenue (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Cost of Revenue	Cost of Revenue Cost of revenue includes the cost of products sold and shipping costs attributable to the revenue. Cost of revenue is included in income from operations of BioPharma’s discontinued Canna-Pet component.

Summary of Significant Accoun23

Summary of Significant Accounting Policies: Shipping Costs (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Shipping Costs	Shipping Costs Shipping costs of $116,287 are included in general and administrative expenses of BioPharma’s discontinued Canna-Pet component.

Summary of Significant Accoun24

Summary of Significant Accounting Policies: Research and Development (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Research and Development	Expenses associated with exploring business opportunities Through the period ended December 31, 2014, we were exploring opportunities related to solutions for the treatment and recycling of waste water resulting principally from oil and gas exploration and productions activities. We determined not to proceed in that industry. Costs included legal fees, fees associated with the assumption of certain notes and other payments under the Agreement, consulting fees, attending conferences, web development, and travel. These costs include a non-cash charge of $102,932 which is the accrued interest on debt assumed and $2,413 which is the fair value of options granted in connection with that business. Research and Development Expenditures for research activities relating to product development and improvement are charged to expense as incurred. We incurred $13,051 and $30,000 in research and development expenses for the years ended September 30, 2015 and 2014, respectively.

Summary of Significant Accoun25

Summary of Significant Accounting Policies: Equity Based Payments (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Equity Based Payments	Equity Based Payments Equity based payments are accounted for in accordance with ASC Topic 718, Compensation – Stock Compensation. The compensation cost is based upon fair value of the equity instrument at the date grant. The fair value has been estimated using the Black-Sholes option pricing model. In addition, payments made to non-employees are accounted for in accordance with ASC Topic 505, Equity-Based payments to Non-Employees.

Summary of Significant Accoun26

Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Income Taxes	Income Taxes The provision for income taxes is determined in accordance with the provisions of ASC Topic 740, Accounting for Income Taxes (“ASC 740”). Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Any effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements, uncertain tax positions taken or expected to be taken on a tax return. Under ASC 740, tax positions must initially be recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions must initially and subsequently be measured as the largest amount of tax benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority assuming full knowledge of the position and relevant facts. For the years ended September 30, 2015 and 2014 we did not have any interest and penalties or any significant unrecognized uncertain tax positions.

Summary of Significant Accoun27

Summary of Significant Accounting Policies: Loss Per Share (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Loss Per Share	Loss per Share We calculate net loss per share in accordance with ASC Topic 260, Earnings per Share. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for the period, and diluted earnings per share is computed by including Common Stock equivalents outstanding for the period in the denominator. We have not issued any potentially dilutive common shares. At September 30, 2015 and 2014 any equivalents would have been anti-dilutive as we had losses for the periods then ended.

Summary of Significant Accoun28

Summary of Significant Accounting Policies: Recent Pronouncements (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Recent Pronouncements	Recent Pronouncements From time to time, new accounting pronouncements are issued that we adopt as of the specified effective date. We believe that the impact of recently issued standards that are not yet effective may have an impact on our results of operations and financial position. ASU Update 2014-15 Presentation of Financial Statements-Going Concern (Sub Topic 205-40) issued August 27, 2014 by FASB defines management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern. The additional disclosure requirement is effective after December 15, 2016 and will be evaluated as to impact and implemented accordingly. In addition, the FASB issued Accounting Standards Update No. 2014-09 (Revenue from Contracts with Customers), which is effective for annual reporting periods beginning after December 15, 2016. We have not yet assessed the impact, if any, of adopting this standard.

Stockholders' Equity and Opti29

Stockholders' Equity and Options: Shareholders' Equity and Share-based Payments (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Shareholders' Equity and Share-based Payments	On March 11, 2014 our board of directors authorized a 1.5 for 1 forward split of our common stock in the form of a stock dividend (the “Stock Split”). In connection therewith, Company shareholders of record as of the close of business on March 27, 2014, the record date, received an additional .5 shares of our common stock for each share of our common stock held by them on the record date. Accordingly, all references to numbers of common shares and per-share data in the accompanying financial statements have been adjusted to reflect the Stock Split on a retroactive basis. On October 10, 2013, we issued 30,000,000 shares at $0.0067 per share, to a then officer of the Company, for total proceeds of $200,000. The shares were valued based upon the prior price paid in a prior transaction as there was no public trading at that time. On March 11, 2014 we repurchased 29,500,000 of these shares for an aggregate of $100,000. Prior to the repurchase, the officer and director resigned. In addition, on October 10, 2013, a former officer and director and a former director of ours delivered to us an aggregate of 300,000,000 shares of common stock of ours for cancellation. The cancellation of these shares was made in conjunction with the resignation of the positions they held. On October 15, 2013, we issued 3,750,000 shares at $0.0067 per share, to two directors of the Company for total proceeds of $25,000. The shares were valued based upon prior price paid in a prior transaction as there was no public trading at that time. On January 30, 2014 in connection with the termination of the JV Agreement and the resignation of the two directors, we repurchased these 3,750,000 shares for $25,000, the amount paid. On November 15, 2013, we issued 1,479,000 shares of our common stock in settlement for $34,510 due to a former related party. The shares were valued at $0.015 per share, the trading value on that date. On March 11, 2014, we issued 37,584,000 shares to 3 individuals and their assignees for services rendered. The shares were valued at $0.0067 per share, the amount paid by the Company to repurchase shares on the same date. The total amount, $250,599 was recognized as equity based compensation. During the period from April through September, we sold a total of 4,075,000 shares of our common stock at a price of $0.20 per share for total proceeds of $815,000. The price per share was negotiated with the investors. There was no cost attributed to these sales. On May 15, 2014 we entered into an agreement for investor relation services. The agreement provided for the issuance of 466,666 shares of our common stock. Pursuant to the agreement the stock was earned in June and July 2014. The stock was valued at $476,000, $1.02 per share, the trading value at the date earned and was charged to expense. On June 25, 2014 we entered into an agreement for public and investor relations services. The agreement is for a period of 90 days. The agreement requires the fee to be settled by our issuance of 60,000 restricted shares of our common stock. The shares were issued on July 14, 2014 and are valued at $61,200, $1.02 per share, the trading value, and has been charged to expense. On June 30, 2014 we issued 3,248,898 shares of our common stock in connection with the conversion of $649,780 in debt as per the debt agreement. On December 22, 2014, pursuant to a Placement Agent Agreement, we issued 200,000 restricted shares of our common stock. The shares were valued at $36,000, $0.18 per share, the trading value, and charged to stock based compensation.

Stockholders' Equity and Opti30

Stockholders' Equity and Options: Options (Policies)	12 Months Ended
	Sep. 30, 2015
Policies
Options	Note 7 – Options In 2013 we issued options to purchase 375,000 shares of our common stock. The options have a term of 10 years, are exercisable at $0.0067 per share and vested twelve months from the date of issuance, October 10, 2013. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $2,413. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 130% Risk Free interest rate 2.71 Dividend yield (on common stock) - During October 2013 through December 31, 2013 we issued options to purchase 1,125,000 shares of our common stock (375,000 to each of our Chief Executive Officer and two Directors). The options had a term of 10 years, were exercisable at $0.0067 per share and vested one year from the date of issuance. In addition, we issued options to purchase 262,500 shares of our common stock to our Chief Financial Officer. The options had a term of 10 years, were exercisable at $0.0067 per share and vested quarterly over the next year. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $5,859. The options have been expensed to the cost of the project which we are not moving forward on. The following assumptions were used in the Black-Scholes option pricing model Expected life (in years) 10 Volatility (based on a comparable companies) 130% Risk Free interest rate 2.71% Dividend yield (on common stock) - In January 2014 all of the option issued to the officers and directors were cancelled. In March 2014, we issued non-qualified options to purchase 2,916,000 shares of our common stock for services rendered to a director of the Company. The options have a term of 10 years, are exercisable at $0.0067 per share and vested when they were issued. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $9,078. The options have been expensed as equity based compensation. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 123% Risk Free interest rate 2.73% Dividend yield (on common stock) - In May 2014, we issued non-qualified options to purchase 4,500,000 shares of our common stock to certain officers of the Company. The options are exercisable at $0.20 per share and have graded vesting over 4 years. The fair value of the options, estimated at the date of grant using the Black-Scholes option pricing model was $4,415,649. The following assumptions were used in the Black-Scholes option pricing model: Expected life (in years) 10 Volatility (based on a comparable companies) 123% Risk Free interest rate 2.56% Dividend yield (on common stock) - As per guidance in the ASC Topic 718, Compensation - Stock Compensation (“ASC 718”), we are amortizing the fair value of the options on a straight line basis over the requisite service period for each separately vesting portion of the award as if the award was, in-substance, multiple awards (graded vesting attribution method). The estimated future expense related to existing stock options is a follows: Years ending September 30, 2016 $ 882,766 2017 407,886 2018 86,961 $ 1,377,613 The following is a summary of outstanding stock options issued to employees and directors as of September 30, 2015: Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding October 1, 2013 - $ - - $ - Issued 8,803,500 $ 0.0067- 0.20 - - Cancelled 1,387,500 $ 0.0067 - - Outstanding September 30, 2014 7,416,000 $ 0.0067 - 0.20 $ - Issued - - - Cancelled - - - Outstanding September 30, 2015 7,416,000 $0.0067 - $0.20 8.57 - Exercisable 4,391,000 $ $0.0067 - $0.20 8.52 $ - The following is a summary of outstanding stock options issued to non-employees, excluding directors, as of September 30, 2015: Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding October 1, 2013 - $ - - $ - Issued 375,000 $0.0067 - Cancelled - - Outstanding September 30, 2014 375,000 $0.0067 - $ - Issued - - Cancelled - - Outstanding September 30, 2015 375,000 $0.0067 8.05 $ - Exercisable 375,000 $0.0067 8.05 $ - Total option expense for the years ended September 30, 2015 and 2014 was $1,828,297 and $1,222,357, respectively.

Summary of Significant Accoun31

Summary of Significant Accounting Policies: Fair Value Measurements: Schedule of Fair Value Measurements (Tables)	12 Months Ended
	Sep. 30, 2015
Tables/Schedules
Schedule of Fair Value Measurements	Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date. The types of assets and liabilities included in Level 1 are highly liquid and actively traded instruments with quoted prices, such as equities listed on the New York Stock Exchange. Level 2 – Pricing inputs are other than quoted prices in active markets, but are either directly or indirectly observable as of the reported date. The types of assets and liabilities in Level 2 are typically either comparable to actively traded securities or contracts, or priced with models using highly observable inputs. Level 3 – Significant inputs to pricing that are unobservable as of the reporting date. The types of assets and liabilities included in Level 3 are those with inputs requiring significant management judgment or estimation, such as complex and subjective models and forecasts used to determine the fair value of financial transmission rights.

Intangibles_ Schedule of Finite

Intangibles: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Tables)	12 Months Ended
	Sep. 30, 2015
Tables/Schedules
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Years ending September 30, Total Amortization 2016 $ 11,667 2017 6,578 $ 18,245

Commitments and Contingencies_

Commitments and Contingencies: Guaranteed Minimum Royalty Payments (Tables)	12 Months Ended
	Sep. 30, 2015
Tables/Schedules
Guaranteed Minimum Royalty Payments	Time Period Minimum Annual License Fee January 1, 2015 through December 31, 2015 Calculated based on gross proceeds equal to twice the verifiable sales of License Based Products for the calendar year ended December 31, 2014, with royalties equal to 15% on gross proceeds of up to $4,000,000 for the year and 10% on gross proceeds in excess of $4,000,000. January 1, 2016 through December 31, 2016 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2017 through December 31, 2017 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2018 through December 31, 2018 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2019 through December 31, 2019 Calculated based on gross proceeds equal to 115% of the amount of gross proceeds used to calculate the minimum royalty for the prior calendar year ended December 31. January 1, 2020 through December 31, 2020, and all succeeding years The minimum annual royalty payment for the calendar year beginning January 1, 2020 and for all subsequent calendar years will be equal to the minimum annual royalty payment calculated for the calendar year ended December 31, 2019.

Stockholders' Equity and Opti34

Stockholders' Equity and Options: Options: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables)	12 Months Ended
	Sep. 30, 2015
Option One
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Expected life (in years) 10 Volatility (based on a comparable companies) 130% Risk Free interest rate 2.71 Dividend yield (on common stock) -
Option Two
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Expected life (in years) 10 Volatility (based on a comparable companies) 130% Risk Free interest rate 2.71% Dividend yield (on common stock) -
Option Three
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Expected life (in years) 10 Volatility (based on a comparable companies) 123% Risk Free interest rate 2.73% Dividend yield (on common stock) -
Option Four
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Expected life (in years) 10 Volatility (based on a comparable companies) 123% Risk Free interest rate 2.56% Dividend yield (on common stock) -

Stockholders' Equity and Opti35

Stockholders' Equity and Options: Options: Schedule of Share-based Compensation, Stock Options, Activity (Tables)	12 Months Ended
	Sep. 30, 2015
Employee
Schedule of Share-based Compensation, Stock Options, Activity	Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding October 1, 2013 - $ - - $ - Issued 8,803,500 $ 0.0067- 0.20 - - Cancelled 1,387,500 $ 0.0067 - - Outstanding September 30, 2014 7,416,000 $ 0.0067 - 0.20 $ - Issued - - - Cancelled - - - Outstanding September 30, 2015 7,416,000 $0.0067 - $0.20 8.57 - Exercisable 4,391,000 $ $0.0067 - $0.20 8.52 $ -
Non-Employee
Schedule of Share-based Compensation, Stock Options, Activity	Number of Options Exercise price per share Average remaining term in years Aggregate intrinsic value at date of grant Outstanding October 1, 2013 - $ - - $ - Issued 375,000 $0.0067 - Cancelled - - Outstanding September 30, 2014 375,000 $0.0067 - $ - Issued - - Cancelled - - Outstanding September 30, 2015 375,000 $0.0067 8.05 $ - Exercisable 375,000 $0.0067 8.05 $ -

Income Tax_ Schedule of Compone

Income Tax: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Sep. 30, 2015
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	2015 2014 Current: Federal $ - $ - State - - Total current - - Deferred: Federal (155,900 ) (350,400 ) State (14,200 ) (31,500 ) Total deferred (170,100 ) (381,900 ) Increase in valuation allowance 170,100 381,900 Total provision $ - $ -

Income Tax_ Schedule of Deferre

Income Tax: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Sep. 30, 2015
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	2015 2014 Net operating loss carryover $ 840,500 $ 381,900

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Details
Accumulated Deficit	$ (6,167,095)	$ (3,859,055)

Summary of Significant Accoun39

Summary of Significant Accounting Policies: Intangible and Long Lived Assets (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Amortization of Website	$ 11,893	$ 4,861

Summary of Significant Accoun40

Summary of Significant Accounting Policies: Shipping Costs (Details)	12 Months Ended
	Sep. 30, 2015USD ($)
Details
Shipping, Handling and Transportation Costs	$ 116,287

Summary of Significant Accoun41

Summary of Significant Accounting Policies: Research and Development (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Accrued Interest on Debt	$ 102,932
Research and Development Expense	$ 13,051	$ 30,000

Discontinued Operations (Detail

Discontinued Operations (Details)	12 Months Ended
	Sep. 30, 2015USD ($)
Details
Disposal Group, Including Discontinued Operation, Inventory, Current	$ 41,705
Disposal Group, Including Discontinued Operation, Other Assets, Current	8,678
Disposal Group, Including Discontinued Operation, Assets, Current	50,383
Disposal Group, Including Discontinued Operation, Accounts Payable	124,396
Disposal Group, Including Discontinued Operation, Other Liabilities, Current	15,341
Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current	179,243
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	(305,295)
Disposal Group, Including Discontinued Operation, General and Administrative Expense	(700,160)
Disposal Group, Including Discontinued Operation, Depreciation and Amortization	(850)
Disposal Group, Including Discontinued Operation, Interest Income	(48)
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	$ 33,040

Intangibles (Details)

Intangibles (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Amortization of Website	$ 11,893	$ 4,861

Intangibles_ Schedule of Fini44

Intangibles: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Details
Estimated Future Amortization Expense 2016	$ 11,667
Estimated Future Amortization Expense 2017	6,578
Intangible Asset, Net of Amortization	$ 18,245	$ 30,139

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Royalty Expense	$ 139,655
Operating Leases, Rent Expense, Net	$ 23,791	$ 4,667

Stockholders' Equity and Opti46

Stockholders' Equity and Options: Shareholders' Equity and Share-based Payments (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Equity Based Compensation	$ 1,828,297	$ 1,222,357
Shares Issued for Debt Conversion (shares)		3,248,898
October 10, 2013
Shares Issued		30,000,000
Shares Issued, Price Per Share		$ 0.0067
Proceeds from Issuance of Common Stock		$ 200,000
Shares Cancelled (Shares)		300,000,000
March 11, 2014
Shares Issued, Price Per Share		$ 0.0067
Shares Repurchased (Shares)		29,500,000
Shares Repurchased		$ 100,000
Stock Issued For Services		37,584,000
Equity Based Compensation		$ 250,599
October 15, 2013
Shares Issued		3,750,000
Shares Issued, Price Per Share		$ 0.0067
Proceeds from Issuance of Common Stock		$ 25,000
January 30, 2014
Shares Repurchased (Shares)		3,750,000
Shares Repurchased		$ 25,000
November 15, 2013
Stock Issued During Period, Shares, Other		1,479,000
Due to Officers or Stockholders, Current		$ 34,510
April through September 2014
Shares Issued		4,075,000
Shares Issued, Price Per Share		$ 0.20
Proceeds from Issuance of Common Stock		$ 815,000
May 15, 2014
Shares Issued, Price Per Share		$ 1.02
Stock Issued For Services		466,666
Shares Issued for Services to Employees and Non-Employees		$ 476,000
June 25, 2014
Shares Issued, Price Per Share		$ 1.02
Restricted Shares of Common Stock (shares)		60,000
Restricted Shares of Common Stock		$ 61,200
June 30, 2014
Shares Issued for Debt Conversion (shares)		3,248,898
Shares Issued for Debt Conversion		$ 649,780
December 22, 2014
Shares Issued, Price Per Share	$ 0.18
Restricted Shares of Common Stock (shares)	200,000
Restricted Shares of Common Stock	$ 36,000

Stockholders' Equity and Opti47

Stockholders' Equity and Options: Options: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	12 Months Ended
	Sep. 30, 2014
Option One
Expected Life	10 years
Volatility	130.00%
Risk Free Interest Rate	2.71%
Option Two
Expected Life	10 years
Volatility	130.00%
Risk Free Interest Rate	2.71%
Option Three
Expected Life	10 years
Volatility	123.00%
Risk Free Interest Rate	2.73%
Option Four
Expected Life	10 years
Volatility	123.00%
Risk Free Interest Rate	2.56%

Stockholders' Equity and Opti48

Stockholders' Equity and Options: Options (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014
Details
Stock or Unit Option Plan Expense	$ 86,961	$ 407,886	$ 882,766
Equity Based Compensation				$ 1,828,297	$ 1,222,357

Stockholders' Equity and Opti49

Stockholders' Equity and Options: Options: Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Employee
Options Outstanding	7,416,000	7,416,000
Exercise Price	$ 0.20	$ 0.20
Average Remaining Term in Years - Options Outstanding	8 years 6 months 25 days
Options Issued		8,803,500
Exercise Price - Options Issued Lower Range	$ 0.0067
Exercise Price - Options Issued Upper Range	0.20
Options Cancelled		1,387,500
Exercise Price - Options Cancelled	$ 0.0067
Options Exercisable	4,391,000
Exercise Price - Options Exercisable	$ 0.20
Remaining Term in Years - Options Exercisable	8 years 6 months 7 days
Non-Employee
Options Outstanding	375,000	375,000
Exercise Price	$ 0.0067	$ 0.0067
Average Remaining Term in Years - Options Outstanding	8 years 18 days
Options Issued		375,000
Exercise Price - Options Issued Upper Range	$ 0.0067
Options Exercisable	375,000
Exercise Price - Options Exercisable	$ 0.0067
Remaining Term in Years - Options Exercisable	8 years 18 days

Interest (Details)

Interest (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Short-term Debt, Lender	Produced Water Solutions
Short-term Non-bank Loans and Notes Payable	$ 602,932
Shares Issued for Debt Conversion (shares)		3,248,898
Effect of Beneficial Conversion Feature		$ 649,780

Income Tax_ Schedule of Compo51

Income Tax: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Deferred Federal Income Tax Expense (Benefit)	$ (155,900)	$ (350,400)
Deferred State and Local Income Tax Expense (Benefit)	(14,200)	(31,500)
Deferred Income Tax Expense (Benefit)	(170,100)	(381,900)
Change in Valuation Allowance	$ 170,100	$ 381,900

Income Tax (Details)

Income Tax (Details) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Income Tax Provision at the Federal Statutory Rate	34.00%	34.00%
State Income Taxes, Net of Federal Benefit	3.10%	3.10%
Effective Income Tax Rate Reconciliation, Percent	(37.10%)	(37.10%)
Valuation Allowance	$ 552,000	$ 381,900
Change in Valuation Allowance	170,100
Operating Loss Carryforwards	$ 840,464

Income Tax_ Schedule of Defer53

Income Tax: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Details
Deferred Tax Assets, Operating Loss Carryforwards	$ 840,500	$ 381,900

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015
Details
Increase/Decrease in Assets of Discontinued Operations Held for Sale	$ 92,671	$ (50,383)